Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome

Medicus Pharma Ltd

Medicus Pharma Ltd

MDCX

0.00
  • Medicus Pharma submitted an FDA Rare Pediatric Disease Designation request for SkinJect to treat basal cell carcinoma in Gorlin syndrome patients.
  • The filing follows an orphan drug designation application; the registrational study design remains under FDA review.
  • Phase 2 data showed 64% clinical clearance, 55% complete response in the 200 ug arm.
  • If granted and later approved, the designation could support eligibility for a rare pediatric disease priority review voucher.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150730PRIMZONEFULLFEED9746756) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.